Project: Nano-Monitoring of Cancer Immunotherapy Efficiency: The Graphene Lateral Electrophoretic Bioassay platform

Acronym	GLEBioassay (Reference Number: EURONANOMED2021-089)
Duration	01/01/2022 - 31/12/2024
Project Topic	GLEBioassay aims to develop a multiplexed point of care nanobiosensing platform to monitor the efficacy of the naxitamab-based immunotherapy in neuroblastoma. Naxitamab is a humanized anti-GD2 monoclonal antibody elicitor of the complement dependent toxicity and the antibody dependent cellular cytotoxicity. It is less immunogenic and more effective than previous chimeric antibody-based immunotherapies and FDA has recently approved its use against refractory/relapsed high-risk neuroblastoma. Some patients can develop human anti-human antibodies (HAHAs), thus provoking the deferment or suspension of the therapy. Conversely, this treatment induces in some patients a vaccine effect, when they start producing their own anti-GD2 antibodies. Currently, there is no standardized and accurate method to determine naxitamab, HAHAs and anti-GD2 in patients undergoing therapy. In this context, the main goal of the project is to develop a novel platform to monitor the pharmacodynamics and pharmacokinetics of naxitamab in real samples, yielding the results in one step. Based on our previous expertise and two recently patented technologies, GLEBioassay will bring an electrophoretical paper-based portable platform with an electrochemical readout for multiplexed immunosensing. In contrast to lateral flow systems where the sample runs through capillarity with optical detection; in our approach the mobility is ruled by electrophoresis enabling a continuous flow, separating its components and cleaning the whole pad. On the other hand, we will use a fast stamping method of laser scribed graphene nanofilms. This technique allows an electrochemical detection using antibodies tagged with electroactive nanoparticles with the advantage of a lower limit of detection and more accurate results. Due to the versatility of the proposed platform, the outcome of the project can also be applied to different scenarios or other immunotherapies where a fast and efficient point of care biosensor is needed.
Website	visit project website
Network	EuroNanoMed III
Call	Joint Transnational Call (2021)

Project partner

Number	Name	Role	Country
1	Fundació Institut Català de Nanociència i Nanotecnologia	Coordinator	Spain
2	Fundació Privada per a la Recerca i la Docència Sant Joan de Déu	Partner	Spain
3	Nehir Biyoteknoloji Ltd.	Partner	Türkiye
4	Palacký University Olomouc	Partner	Czech Republic